PedAM
Pediatric Disease Annotations & Medicines
| Disease | endocarditis |
| Phenotype | C0002871|anemia |
| Sentences | 1 |
| PubMedID- 21701620 | An additional phase i trial combining sunitinib (37.5 mg in the 4 weeks on/2 weeks off schedule) and everolimus (daily or weekly regimen) reported at the 2009 asco annual meeting revealed a significant dose limiting toxicity when the two agents were combined.21 the severe adverse events included endocarditis, gastrointestinal hemorrhage with severe anemia and pulmonary embolism. |
Page: 1